CLAIMS

(1) A combination of a cyclodextrin compound and a budesonide derivative selected from budenoside, mometasone, fluticasone, betamethasone, beclomethasone and their pharmaceutically acceptable salts for use in the preparation of a medicament for decreasing the level of CXCL-1 and/or IL17 and thereby treating or preventing pulmonary inflammatory disease in a host mammal.

2. Use according to Claim 1, in which the cyclodextrin compound is hydroxypropyl β-cyclodextrin.

3. Use according to Claim 2, in which the pharmaceutical composition comprises about 250 μg/ml budesonide and about 20 mM HP-β-CD.

4. Use according to Claim 2, in which the pharmaceutical composition comprises about 100 μg/ml budesonide and about 20 mM HP-β-CD.

5. Use according to Claim 2, in which the pharmaceutical composition comprises about 250 μg/ml budesonide and about 10 mM HP-β-CD.

6. Use according to Claim 2, in which the pharmaceutical composition comprises about 100 μg/ml budesonide and about 10 mM HP-β-CD.

7. Use according to Claim 2, in which the pharmaceutical composition is for delivering the budesonide derivative in a molecular dose in a range of from about 50 to about 200 mcg per day.

8. Use according to any preceding claim, in which the pharmaceutical composition comprises a solution having a pH of from about 7 to about 7.5

9. Use according to Claim 1 or 2, in which the pharmaceutical composition comprises a complex of a budesonide derivative and a cyclodextrin compound in a stoichiometric ratio of about 1:1.

10. Use according to any preceding claim, in which the pharmaceutical composition is capable of decreasing CXCL-1 levels in a host mammal.

11. Use according to Claim 10, in which the pharmaceutical composition is capable of decreasing ozone-induced CXCL-1 production in lung tissue in a host mammal.

12. Use according to Claim 9, in which the pharmaceutical composition is capable of decreasing the level of CXCL-1 in a host mammal and thereby reducing neutrophil chemoattraction to the bronchial walls of the mammal.

13. Use according to any of Claims 1 to 9, in which the pharmaceutical composition is capable of decreasing the level of IL-17 in a host mammal.

14. Use according to any preceding claim, in which the reduction in the level of CXCL-1 and/or IL17 reduces neutrophil number in the bronchoalveolar lavage fluids of the host mammal.

15. Use according to any preceding claim, in which the pulmonary inflammatory disease is chronic obstructive pulmonary disease.